- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Heartland Oncology & Hematology to Join the American Oncology Network, LLC
American Oncology Network, LLC (AON) is pleased to announce that Heartland Oncology & Hematology, a leading community oncology/hematology practice in Council Bluffs, Iowa, will be joining AON, effective November 1, 2019.
FORT MYERS, FLA., October 8, 2019 — American Oncology Network, LLC (AON) is pleased to announce that Heartland Oncology & Hematology (HOH), a leading community oncology/hematology practice in Council Bluffs, Iowa, will be joining AON, effective November 1, 2019. AON is an alliance of physicians and veteran healthcare leaders partnering to ensure the long-term success of community oncology.
By affiliating with the national professional services organization, HOH will increase its current service offerings to cancer patients at its multiple locations in Iowa. HOH will now provide an expanded oral oncolytic outpatient pharmacy, pathology and central laboratory services, care management and enhanced technology.
Brad Prechtl, MBA, CEO of AON, stated, “We are excited to welcome the entire Heartland Oncology & Hematology team to the American Oncology Network. Heartland Oncology & Hematology represents a commitment to serving and supporting patients through southwest Iowa and Eastern Nebraska with exceptional cancer care in a community setting,” said Prechtl.
For more information, see the full press release here.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
